MSD pulls plug on cholesterol drug anacetrapib
MSD has decided to pull the plug on its late-stage cholesterol drug anacetrapib after a review of clinical data.
Read More
Tag: anacetrapib
MSD’s CETP inhibitor cuts heart risk by 9 percent
MSD has revealed that its CETP inhibitor anacetrapib reduced the risk of major coronary events by 9 percent versus placebo in patients with cardiovascular disease already taking LDL-C lowering therapy alongside atorvastatin.
Read More
MSD’s CETP inhibitor lowers risk of cardiac events
MSD’s CETP inhibitor anacetrapib has hit its key target in the late-stage REVEAL study, showing a significant reduction in major coronary events in at-risk patients already on a cholesterol-lowering regimen.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
